Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GUIDANCE: De-Intensification and Intensification Clinical Trial Evaluation in Prostate Cancer
NCT05050084Phase 3Active, not recruiting
- Sponsor
- NRG Oncology
- Start
- Dec 2021
- Primary completion
- Nov 2026
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of darolutamide in prostate adenocarcinoma (4 arms), sponsored by NRG Oncology. Primary endpoints: Distant Metastasis at 5 years and Metastasis-Free Survival at 5 years. Started Dec 2021; status: active, not recruiting.
02
Drugs
darolutamide
03
Conditions
prostate adenocarcinoma
Beyond the preview
Go deeper on NCT05050084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05050084.